AI Article Synopsis
- Primary mediastinal large B-cell lymphoma (PMBCL) is a rare type of lymphoma that usually responds well to standard treatment but poses challenges for relapsed cases unable to undergo stem cell transplantation.
- A patient with refractory PMBCL, who did not respond to salvage chemotherapy, was treated with a combination of nivolumab (an immunotherapy) and radiotherapy.
- Remarkably, the patient achieved complete remission, experienced only mild side effects, and has remained relapse-free for 2 years following treatment.
Article Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394502 | PMC |
| http://dx.doi.org/10.2147/CMAR.S254007 | DOI Listing |
Publication Analysis
Top Keywords
nivolumab radiotherapy
8
primary mediastinal
8
mediastinal large
8
large b-cell
8
b-cell lymphoma
8
combining pd-1
4
pd-1 inhibitor
4
inhibitor nivolumab
4
radiotherapy treated
4
treated patient
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!